led to the conclusion that the mutant protein's dominant negative effect could be diluted, obviating the need to remove the mutant protein completely, in order to obtain a normal phenotype.
Although the majority of keratin mutations are dominant negative, a small number of recessively inherited mutations have been identified in patients with epidermolysis bullosa simplex (EBS) (Chan et al., 1994; Rugg et al., 1994; Jonkman et al., 1996; Landschuetzer et al., 2003) . These are generally null mutations, in which there is no product from the defective gene; thus, they are silent in the heterozygous state. It is interesting that only K14-null mutations have been reported, and the absence of K5 (polymerization partner of K14) has never been identified. This implies that K5-null epidermal stem cells cannot survive (embryo lethal). Nonsense and some frameshift mutations can introduce premature termination codons in the N-terminal portion of such proteins, and the resulting unstable mRNA is then removed as a consequence of triggering nonsense-mediated decay (Chang et al., 2007) . This effectively silences the gene and leads to an absence of protein from the mutant allele. In a heterozygous setting this would be clinically unremarkable, but in a homozygous state a disease phenotype will result because of the total absence of protein. Interestingly, nonsense-mediated decay has also been observed in patients with recessive forms of epidermolytic hyperkeratosis caused by homozygous KRT10 nonsense mutations (Terheyden et al., 2009) .
are null-state mutations less disruptive than dominant negative mutations?
Null mutations cause a functional absence of one member of a keratin pair. Although this weakens the IF network within the cell, it is thought to be less disruptive than the continued presence of mutant keratin protein aggregates. Research presented by D' Alessandro et al. (2011, this issue) and in other publications (Batta et al., 2000; Landschuetzer et al., 2003) 
Keratin genodermatoses: a dominant negative theme
A link between keratin defects and a group of genetic skin fragility disorders became apparent in the early 1990s. Research into the function of the intermediate filament (IF) network in cells indicated that disruption to the C-terminal portion of a keratin monomer would collapse the IF network, significantly weaken the cell, and lead to skin disease in mice (Vassar et al., 1991) . IF collapse occurred in both cultured cells and transgenic mice, even though mutant proteins comprised only 50% of the specific keratin involved and this represented only 25% of the total keratin in the filament (obligatory hetero polymers require two different keratin subunits, a product of four alleles). This dominant negative effect was thought to pose an impenetrable barrier to successful gene therapy because the mutant protein would need to be removed before any introduced wild-type protein could have a corrective effect. However, later evidence from studies of patients with phenotypic and genotypic mosaicism et al., 2002; Russell et al., 2010) . This logic is supported by the observation that heat shock gave rise to keratin aggregates only in cells carrying a dominant negative mutation (and not in K14-null cells). However, different causes of null mutations can produce phenotypes of variable severity (Chan et al., 1994; Batta et al., 2000) . It has been known for some time that disease severity in patients bearing keratin mutations depends somewhat on the position of the mutation (Letai et al., 1993) and the actual change (e.g., amino acid substitution, insertion, deletion, splice defect) that occurs. Variability is apparent in D'Alessandro and colleagues' study, in which the K14-null status resulted from two different mutations (in two different families) (see Rugg et al., 1994, and Jonkman et al., 1996) . The resulting K14-null cell lines behaved differently in migration assays: KEB-11 responded in a manner similar to that of normal NEB-1 cells, whereas KEB-13 responded in a manner similar to that of KEB-7 (a dominant negative cell line). However, altered migration was normalized in both cell lines by the addition of wild-type K14. Also, whereas K14-null cells were clearly stressed, the levels of JNK phosphorylation detected were not as high as those observed for dominant negative mutations (e.g., KEB-7); again, the addition of wild-type K14 reduced these levels to normal.
The question of compensatory expression of other keratins in a null situation is also a matter of some debate. In the absence of K14, it has always been assumed that other type I keratins are overexpressed and copolymerize with the unpaired K5. However, although the K14-null cells can be clearly shown to have an IF network, identification of the type I partner is more of a challenge. Although D'Alessandro et al. demonstrated that K14-null cells expressed K17, K18, and K19, little change in expression levels was observed compared with normal keratinocytes, and the copolymerizing keratin in the K14-null cells was not identified. However, earlier studies of K14-null mutations implicated a limited compensatory role for K15 (Jonkman et al., 1996) .
Genotype-phenotype relationships: understanding the effect of keratin mutations
Thus, in keratin genodermatoses, the relationship between a mutated gene and the resulting altered cutaneous cellular pathology in a specific patient can be complex. Even within a family, the same mutation can produce different phenotypes. In EBS, some mutations in the early 1A helical region (p.N176S and p.F179S in K5, for example) caused a severe phenotype (Stephens et al., 1997) , but a similar mutation between these two codons (p.N177S in K5) produced a mild phenotype (Liovic et al., 2004) . Thus, it is not only the gross location of the mutation but also the functional effect of altering specific codons that influences phenotype. The genetic background of an individual also plays an important role in the effect of a given mutation, and there has been much discussion concerning the role of modifier genes. Thus, if genes can be identified that ameliorate the pathophysiology that results from disease-causing mutations, then overexpression of such genes may prove beneficial in terms of therapy.
Natural reversion is a rare event, but there have been reports of a few instances. Partial reversion was observed in a patient with recessive EBS caused by a homozygous K14 splice mutation and leading to an absence of viable transcripts (Schuilenga-Hut et al., 2002) . However, skin biopsy revealed mosaic expression of K14 in basal epidermal cells, and further investigation revealed an additional K14 transcript that was able to reconstitute the IF network. The phenotype was not improved because this new transcript was also abnormal but not susceptible to nonsense-mediated decay.
More recently, mitotic recombination has been shown to cause reversion of a dominant negative mutation in KRT10, resulting in a phenotype termed ichthyosis with confetti (also known as congenital reticular ichthyosiform erythroderma). A group of mutations in the intron 6-exon 7 boundary region of KRT10 results in a frameshift that creates an arginine-rich C-terminal peptide in K10. This altered K10 protein is sequestered from the IF network into the nucleolus, causing cellular fragility, altered differentiation, and parakeratosis. However, patients with ichthyosis with confetti exhibit extensive somatic loss of heterozygosity of the mutant locus on chromosome 17; this generates islands of normal skin attributable to positive selective pressure on stem cells with a wild-type profile presenting as white areas on a red background (Choate et al., 2010) .
Epidermolytic hyperkeratosis (EHK) also exists as a mosaic, a condition called linear epidermal nevus, in which clones of normal cells are interspersed with mutant cells. Causal mutations have been identified in KRT10 (Moss et al., 1995) , but the main point of interest is that normal skin adjacent to the nevi has a mixture of normal and mutant cells, with normal cells predominant. This implies that complete correction of dominant negative keratin mutations et al., 2009) . Currently, research is aimed at removing the product of a mutant allele by targeting the mRNA carrying the mutation. This requires high specificity because in the majority of patients only a single base change is involved. Early attempts were made by designing ribozymes, but more specific targeting has been possible using small interfering RNA (siRNA) silencing technology (Lewin et al., 2005) . Recent work on pachyonychia congenita type 1 (PC1), caused by dominant negative mutations in KRT6A (or KRT16), has indicated that siRNA knockdown sufficient to correct the phenotype can be achieved in cultured cells and in mouse models (Leachman et al., 2008) . This technology is currently being evaluated in phase I clinical trials as a means of treating patients with PC1.
Another route for cutaneous gene therapy is to correct stem cells in an ex vivo setting and then to apply the corrected cells to the patient's skin. It has been shown in mouse models that corrected stem cells can repopulate stem cell niches in the skin (Arin and Roop, 2004) . However, these cells are corrected using adenovirus or lentivirus vectors, and they can be susceptible to reversion over time (Lewin et al., 2005) . There can also be significant hurdles to reapplying cells to the skin of patients because the presence of any viral DNA sequences may trigger an immune response.
A third route to correcting cutaneous genodermatoses would be to leave the defective gene in place and tackle the factors that cause the phenotype. Augmentation of wild-type keratins or their paralogs (such as K15 induction to supplement loss of K14) might be able to stabilize the IF network even in the presence of mutant protein. Blocking the cellular stress response to protein aggregates may prevent the cell from entering a self-destructive cycle.
concluding remarks D'Alessandro and colleagues have demonstrated that K14-null cells can be rescued by the addition of wild-type protein and that the stress responses associated with keratin disorders can be ameliorated. More work is needed on cells that contain mutant keratin proteins to assess whether replacing wild-type protein can overcome the dominant negative effect of the mutation or whether the only way forward in the majority of keratin disorders is to silence the mutant protein.
Furthermore, although correction in cultured cells and in mouse models is an important prerequisite for gene therapy approaches in patients, obstacles still exist in terms of successful corrective gene therapy in vivo.
